References
- Salvatore Minisola, Munro Peacock, Seijii Fukumoto, et al.
Tumour-induced osteomalacia. Nature Reviews Disease Primers
2017;volume 3:Article number: 17044.
- Bosman A, Palermo A, Vanderhulst J, et al. Tumour-induced
osteomalacia: A Systematic Clinical Review of 895 Cases. Calcif Tissue
Int 2022;111(4):367–379.
- Hidaka N, Koga M, Kimura S, Hoshino Y, et al. Clinical Challenges in
Diagnosis, Tumor Localization and Treatment of Tumor-Induced
Osteomalacia: Outcome of a Retrospective Surveillance. J Bone Miner
Res 2022;37(8):1479–1488.
- Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most
osteomalacia-associated mesenchymal tumors are a single
histopathologic entity: an analysis of 32 cases and a comprehensive
review of the literature. Am J Surg Pathol 2004;28:1–30.
- Pelo S, Gasparini G, Garagiola U, et al. Phosphaturic mesenchymal
tumor, an unusual localization in head and neck. J Surg Case Rep
2018;22;5.
- Arnaoutakis D, Naseri I. Sinonasal Phosphaturic Mesenchymal Tumor: A
Rare and Misinterpreted Entity. J Neurol Surg Rep
2015;76(2):e233–238.
- Komínek P, Stárek I, Geierová M, Matoušek P, Zeleník K. Phosphaturic
mesenchymal tumour of the sinonasal area: case report and review of
the literature. Head Neck Oncol 2011;3:16.
- Li X, Jiang Y, Huo L, et al. Nonremission and Recurrent Tumor-Induced
Osteomalacia: A Retrospective Study. J Bone Miner Res
2020;35(3):469–477.
- Kato H, Koga M, Kinoshita Y, et al. Utility of Multimodality Approach
Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic
Mesenchymal Tumors. J Endocr Soc 2022;7(2):181.
- Ito N, Kubota T, Kitanaka S, et al. Clinical performance of a novel
chemiluminescent enzyme immunoassay for FGF23. J Bone Miner Metab
2021;39(6):1066–1075.
- Kato H, Hidaka N, Koga M, et al. Performance evaluation of the new
chemiluminescent intact FGF23 assay relative to the existing assay
system. J Bone Miner Metab 2022;40(1):101–108.
- Amin MB, Edge SB, Greene FL, et al, editors. AJCC Cancer Staging
Manual. 8th edn. Switzerland: Springer, 2017.
- Abuhejleh H, Wunder JS, Ferguson PC, et al. Extended intralesional
curettage preferred over resection-arthrodesis for giant cell tumour
of the distal radius. Eur J Orthop Surg Traumatol 2020 Jan;30(1):
11–17.
- Kobayashi K, Nakao K, Kawai K, et al. Tumor-induced osteomalacia
originating from the temporal bone: a case report. Head Neck
2011;33(7):1072–1075.
- Mori Y, Ogasawara T, Motoi T, et al. Tumor-induced osteomalacia
associated with a maxillofacial tumor producing fibroblast growth
factor 23: report of a case and review of the literature. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 2010;109(3):e57–63.
- Acharya RP, Won AM, Moon BS, et al. Tumor-induced hypophosphatemic
osteomalacia caused by a mesenchymal tumor of the mandible managed by
a segmental mandibulectomy and microvascular reconstruction with a
free fibula flap. Head Neck 2019;41(6):E93–E98.
- Qari H, Hamao-Sakamoto A, Fuselier C, Cheng YS, Kessler H, Wright J.
Phosphaturic Mesenchymal Tumor: 2 New Oral Cases and Review of 53
Cases in the Head and Neck. Head Neck Pathol 2016;10(2):192–200.
- Pal R, Bhadada SK, Singhare A, et al. Tumor-induced osteomalacia:
experience from three tertiary care centers in India. Endocr Connect
2019;8(3):266–276.
- Zhu Z, Xia W, Qi F, et al. Clinical characteristics and surgical
outcomes of sinonasal lesions associated with tumor-induced
osteomalacia. Otolaryngol Head Neck Surg 2021;165(1):223–231.
- Shah R, Lila AR, Jadhav RS, et al. Tumor induced osteomalacia in head
and neck region: single center experience and systematic review.
Endocr Connect 2019;8(10):1330–1353.
- Kobayashi H, Makise N, Ito N, et al. Surgical margin for phosphaturic
mesenchymal tumors in soft tissues: An analysis of the radiological
histopathological correlation. J Orthop Sci 2021;26(5):870–877.
- Kobayashi H, Makise N, Ushiku T, et al. Infiltrative nature of
tumor-induced osteomalacia lesions in bone: Correlation between
radiological and histopathological features. J Orthop Sci
2019;24(5):900–905.
- Haffner D, Emma F, Eastwood DM, et al. Clinical practice
recommendations for the diagnosis and management of X-linked
hypophosphataemia. Nat Rev Nephrol 2019;15(7):435–455.